Technologieangebote

Anti CD30 CAR – Anti CD30 chimeric antigen receptor selectively targets tumor cells

Adoptive T-cell therapy has recently shown promise in initiating a lasting anti-tumor response with spectacular therapeutic success in some cases. Of particular interest are T-cells, which have been specifically redirected by engineering with a chimeric

antigen receptor (CAR). The CAR consists in the extracellular part of an antibody-derived domain for binding with a “tumor-associated antigen” and in the intracellular part of a Tcell receptor-derived signaling moiety for Tcell activation.

Weitere Informationen: PDF

PROvendis GmbH
Tel.: +49 (0)208/94105 10

Ansprechpartner
Dipl.-Ing. Alfred Schillert

Kommentare (0)

Schreiben Sie einen Kommentar